GABITRIL Home Page
GABITRIL Home Page

Important Safety Update
GABITRIL Overview

Selective GABA Reuptake Inhibition
Safety
Drug Interactions
Dosing/Pharmacokinetics
Epilepsy

The Role of GABA in CNS
Patient Education
News & Research
Prescribing Information
Get GABITRIL Information

 

Dosing guidelines for GABITRIL have been established only for its use as an adjunctive treatment for partial seizures and not for any other condition



GABITRIL Offers Convenient Dosing With Easy-to-Swallow Tablets1,2
The following dosing recommendations apply to all patients taking GABITRIL:
  • GABITRIL is given orally and should be taken with food
  • Do not use a loading dose of GABITRIL
  • Dose titration: Rapid escalation and/or large dose increments of GABITRIL should not be used
  • Missed dose(s): If the patient forgets to take the prescribed dose of GABITRIL at the scheduled time, the patient should not attempt to make up for the missed dose by increasing the next dose. If a patient has missed multiple doses, patient should refer back to his or her physician for possible re-titration as clinically indicated.
  • Dosage adjustment of GABITRIL should be considered whenever a change in patient's enzyme-inducing status occurs as a result of the addition, discontinuation, or dose change of the enzyme-inducing agent
GABITRIL Offers a Favorable Pharmacokinetic Profile1,3
  • Linear pharmacokinetics offer predictable systemic exposure
  • Rapid absorption with peak plasma levels occurring approximately 45 minutes after dosing in a fasting state
  • GABITRIL pharmacokinetics are linear (2-24 mg single dose)

GABITRIL is only indicated as adjunctive therapy in adults and children 12 years and older in the treatment of partial seizures. Cephalon, Inc. does not recommend the use of GABITRIL for any other indication.

References:
1. GABITRIL package insert, Cephalon, Inc.
2. Data on file, Cephalon, Inc.
3. Gustavson LE, Mengel HB. Pharmacokinetics of tiagabine, a g-aminobutyric acid-uptake inhibitor, in healthy subjects after single and multiple doses. Epilepsia. 1995;36:605-611.